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Classical Activation of Macrophages and Vardenafil 
 
Vardenafil (Levitra; GlaxoSmithKline, UK) is a member of a class of highly selective inhibitors 
of cGMP-dependant phosphodiesterase (PDE) type 5, a class of drugs which includes 
sildenafil, tadalafil and udenafil, which is approved for the treatment of pulmonary arterial 
hypertension and erectile dysfunction.[1] Sildenafil (Viagra; Pfizer Inc, USA), vardenafil, and 
udenafil, but not tadalafil (Cialis; Eli Lilly, USA), inhibit PDE6 with substantially lower affinities 
than those for PDE5A. Tadalafil has been shown to potently inhibit PDE11A activity still much 
less potently than it does PDE5A.[2]  The selectivity and successful application of these PDE 
inhibitors as treatment of erectile dysfunction and more recently for pulmonary hypertension 
has validated the emergence of PDEs as drug targets.[1, 3]  It is also likely that potential new 
applications for these drugs will emerge as PDE involvement in new diseases, signalling 
pathways and cellular processes is identified. 
Cystic Fibrosis (CF) is a monogenic disorder resulting from mutations in the CF 
transmembrane conductance regulator (CFTR, ABCC7) gene which encodes the main 
chloride channel expressed in epithelia of respiratory, digestive and reproductive systems.[4] 
Majority CF patients (70%) carry at least one allele of F508del-CFTR and manifest defective 
airway mucociliary clearance, persistent infection and inflammation leading to end-stage lung 
damage.  Recent reports have provided evidence that phosphodiesterase type 5 (PDE5) 
inhibitors, including vardenafil, rescued F508del-CFTR trafficking and corrected deficient 
chloride transport activity and are potential agents to attenuate exaggerated lung inflammatory 
responses in CF.[5-9] 
PDE are expressed ubiquitously in inflammatory cells and regulate intracellular cyclic 
nucleotide (cAMP/CGMP) levels and as such, selective PDE inhibitors offer novel therapeutic 
strategies for treatment of various inflammatory diseases including asthma, inflammatory 
bowel disease, chronic obstructive pulmonary disease, psoriasis and CF. For example, PDE4 
is a major cyclic AMP metabolizing enzyme in inflammatory cells, and PDE4 inhibitors produce 
a wide range of anti-inflammatory and immunomodulatory effects; they reduce neutrophil 
trafficking to sites of inflammation, release of neutrophil products, leukotriene B4 (LTB4), IL-8, 
reactive oxygen species and promote neutrophil apoptosis. [10-13]  Poschet et al 
demonstrated that pharmacological inhibition of PDE5 attenuated CF pro-inflammatory 
responses; they showed that in cell models and airway of mice infected with Pseudomonas 
aeruginosa, sildenafil reduces bacterial adherence and neutrophil lung inflammation, 
respectively.[8] Lubamba et al found that vardenafil attenuates the expression of pro-
inflammatory cytokines (e.g. IL-1B) and chemokines (e.g. monocyte/macrophage chemo-
attractant CCL-2) and cell infiltrates in the bronchoalveolar lavage of both wild type and 
F508del-CF mice [9]   
Macrophages are mononuclear immune cells derived from monocytes. Different 
subspecialties of macrophages exist in various organs or locations throughout the body.[14]  
They play a key role in both innate and adaptive immunity and phagocytise invading 
microorganisms as well as apoptotic and necrotic cells of the host, secrete mediators of 
inflammation, and present antigens to T cells.[15]  In response to various signals of exogenous 
and endogenous origin, macrophages polarize or undergo activation, and acquire different 
functional properties - leading to pro-inflammatory (M1) or anti-inflammatory (M2) 
phenotypes.[16, 17]  The polarized macrophages may differ in terms of receptor expression, 
cytokine production, effector function and chemokine repertoires and show considerable 
plasticity between the two extreme phenotypes.  M1 macrophages are characterized by high 
capacity to present antigen; high interleukin-12 (IL-12), IL-23, IL-1 and IL-6 production and 
consequent activation of a polarized type I response; and high production of toxic 
intermediates [nitric oxide (NO), reactive oxygen intermediates (ROI)]. [18, 19]  Potent key 
activators of the macrophage response such as interferon- (IFN-), alone or together with 
microbial endotoxins (e.g. lipopolysaccharide (LPS)) or cytokines (e.g. tumour necrosis factor 
(TNF)), bind to macrophage receptors (e.g. CD14, TLR) and drive classical activation or M1 
polarization of macrophages with potentiated cytotoxic and anti-tumoural properties.  
Consequently, classically activated M1 macrophages are potent effector cells which kill 
microorganisms and tumour cells and produce copious amounts of proinflammatory cytokines. 
However, uncontrolled release of these mediators can be dangerous for the host tissue – a 
typical example being the airway of CF patients.  
In this issue of the Journal (pp----), Noel et al [20] provide evidence that macrophages are the 
target effector cells through which vardenafil modulates CF airway inflammation. Previous 
studies had shown that macrophages contribute significantly to the exaggerated inflammation 
in CF lung disease; macrophages from CF mice display exaggerated pro-inflammatory 
responses [21], and the differentiation pattern of cultured alveolar and peritoneal 
macrophages in F508del-CFTREUR mice is altered towards a pro-inflammatory status (M1) 
[22]. Noel et al [20] evaluated pro-inflammatory responses driven by M1 polarization in lung 
macrophages from F508del-CFTR and wild-type mice and showed exaggerated pro-
inflammatory responses in CF macrophages.  Treatment with vardenafil downregulated the 
overresponses of M1 markers (NOS-2 and TNF-g) in CF cells. In this regard, it is interesting 
that increased cGMP was previously shown to inhibit release of TNFg and nitric oxide in cells 
of myeloid lineage activated with LPS. [23, 24]  Intracellular accumulation of cGMP can be 
achieved by stimulating its formation (i.e. by means of guanylyl cyclase agonists) or by 
inhibiting its degradation (i.e. by means of phosphodiesterase (PDE) inhibitors).  By catalyzing 
the hydrolysis of guanosine 3’ 5’ cyclic monophosphate (cGMP), the enzyme regulates the 
intracellular levels of the cGMP second messenger (Figure 1). Using siRNA experiments, Noel 
et al [20] confirmed a role for PDE5 in modulating inflammatory responses of CF M1 activated 
macrophages. Interestingly, they also observed that the effect of vardenafil to downregulate 
M1 polarization requires CFTR expression and was not observed in cftr-/- null mice indicating 
that M1 overresponses in CF are related to the loss-of-function of CFTR.  The precise nature 
of interaction between PDE5 and CFTR or CFTR mutation and macrophage polarisation is as 
yet not understood.  Interestingly, although the mechanism by which CFTR regulates the major 
innate immune response pathways is still unclear, expression of CFTR on the membrane 
inhibits the pro-inflammatory signaling via inflammatory (TNFg, TLR or IL-1く) pathways, which 
regulate NF-せB activation and IL-8 secretion. [25] 
The activation of intracellular signaling pathways in activated macrophages leads not only to 
synthesis of nitric oxide (NO) and the proinflammatory cytokines, TNFg, IL-6, Il-1く but to 
elevated expression of other proteins to facilitate fast development of an inflammatory 
response. For example, PDE4B is up-regulated by LPS and is responsible not only for cAMP 
hydrolysis and thereby removing the anti-inflammatory effects of cAMP but for synthesis of 
TNFg induced by LPS [26, 27]. On the other hand, cyclic GMP (cGMP) has been shown to 
inhibit hydrolysis of cAMP by PDE3 and is involved in the regulation of expression of 
inflammatory cytokines in macrophages. [28]  See Figure 1.  
Human macrophages have been shown to contain PDE1, PDE3, PDE4, and PDE5.[28, 29]  
Until now, partly due to the absence of specific tools or inhibitors, the identity and significance 
of cGMP-regulated PDEs that are actively expressed or functional in activated macrophages 
was unknown.  The findings by Noel et al have highlighted a cGMP-PDE5 lesion or 
dysregulation in CF and should lead to full characterisation of the proteins involved in cGMP 
signaling and M1 macrophage polarisation or activation.  Increasing evidence indicates that 
cGMP plays an important role in regulating essential functions of macrophages such as 
chemotaxis, phagocytosis, cytotoxicity, and synthesis of inflammatory mediators [23, 24, 27, 
30-32], and thus, controls the macrophage inflammatory response. Eleven families of 
phosphodiesterases have been identified in mammalian tissues and classified according to 
amino acid sequence, substrate specificity, pharmacological properties and tissue distribution; 
among them - five (PDE1, PDE2, PDE3, PDE10, and PDE11) hydrolyze both cAMP and 
cGMP, three (PDE4, PDE7, and PDE8) are cAMP-specific, and only three (PDE5, PDE6, and 
PDE9) are exclusively cGMP-specific. [33]  The activity profile of PDE’s which hydrolyze 
cGMP and are regulated by cGMP will also need to be determined in polarised macrophages. 
Interestingly, analysis of peritoneal macrophage PDE activity profile shows soluble PDE5 
activity is low and undetectable in the particulate fraction of the macrophage.[34, 35]  It has 
been suggested PDEs whose total activity level is low could still contribute significantly to 
cellular function by controlling an important microdomain within the cell. [36-38]  Thus 
involvement of PDE5 with CFTR, a transmembrane protein resident in the phagosome and 
plasma membrane in macrophages [39, 40], suggests PDE5 might exist in a multi-protein 
complex with CFTR in a discrete compartment within the cell to limit the spread of the second 
messenger cGMP.  Interestingly, in rat jejenum, cGMP effect on CFTR-dependent fluid 
secretion was inhibited by PKG inhibitors. [41] 
Finally, the finding by Noel et al that regulation of PDE5 by vardenafil modulates macrophage 
function and exaggerated inflammatory response in CF will stimulate further research in this 
area. For example, the precise cGMP targets and signalling pathway(s) that lead to 
downregulation of M1 macrophage pro-inflammatory markers (NOS-2 and TNF-g) in CF, 
following vardenafil treatment, remain to be identified. Identification and characterization of 





Figure 1.  Potential down-stream effectors of PDE5 inhibition by vardenafil in macrophage. 
NO – Nitric Oxide, sGC – soluble guanyl cyclase, AC – adenylyl cyclase. GAFs - cGMP 
binding domains.  PKA/PKG can be cross activated by cAMP and cGMP. Compounds such 
as vardenafil that rescue CFTR to the cell surface or lipid-rafts can block NF-せB mediated 
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